An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial  Douglas L. Seidner, Bret A. Lashner, Aaron Brzezinski, Phillip L.C. Banks, John Goldblum, Claudio Fiocchi, Jeffry Katz, Gary R. Lichtenstein, Peter A. Anton, Lori Y. Kam, Keith A. Garleb, Stephen J. Demichele  Clinical Gastroenterology and Hepatology  Volume 3, Issue 4, Pages 358-369 (April 2005) DOI: 10.1016/S1542-3565(04)00672-X Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Plasma phospholipid concentrations of AA, EPA, and DHA in completed patients receiving either placebo (n = 50) or UCNS (n = 36) at baseline and after 3 and 6 months of study. Values are means ± SE. *P < .001 vs. placebo. Clinical Gastroenterology and Hepatology 2005 3, 358-369DOI: (10.1016/S1542-3565(04)00672-X) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Plasma concentrations of α-tocopherol and β-carotene in completed patients receiving either placebo (n = 50) or UCNS (n = 36) at baseline and after 3 and 6 months of study. Values are means ± SE. *P < .001 vs. placebo. Clinical Gastroenterology and Hepatology 2005 3, 358-369DOI: (10.1016/S1542-3565(04)00672-X) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 3 Change from baseline of average prednisone dose by study month. The negative values indicate that the average dose for a patient at a particular month decreased relative to the baseline level. The baseline doses of prednisone for intent-to-treat (11.1 mg for placebo, n = 62; and 10.3 mg for UCNS, n = 59) and completed (12.9 mg for placebo, n = 50; and 13.4 mg for UCNS, n = 36) patients were not different between groups (P > .1). Clinical Gastroenterology and Hepatology 2005 3, 358-369DOI: (10.1016/S1542-3565(04)00672-X) Copyright © 2005 American Gastroenterological Association Terms and Conditions